Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2012

01-02-2012 | Original Article

Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography

Authors: Kunihiko Izuishi, Yuka Yamamoto, Takanori Sano, Ryusuke Takebayashi, Yoshihiro Nishiyama, Hirohito Mori, Tsutomu Masaki, Asahiro Morishita, Yasuyuki Suzuki

Published in: Journal of Gastrointestinal Surgery | Issue 2/2012

Login to get access

Abstract

Background

Biological imaging by positron emission tomography (PET) using 18F-2-fluoro-2-deoxy-d-glucose (FDG) has been widely used clinically for the detection of primary tumors and for early prediction of response to chemotherapy. In this study, we examined the molecular mechanism underlying the detection of colorectal cancers by FDG-PET.

Material and Methods

In all, 37 patients with colorectal cancer were examined with FDG-PET, and the maximal standardized uptake value (SUV) was calculated. Using surgical tissue samples, we examined the expression levels of hypoxia-inducible factor alpha (HIF1α), a marker of tissue hypoxia; proliferative cellular nuclear antigen (PCNA), a marker of proliferation; and glucose transporter (GLUT)1 and hexokinase (HK)2, protein of glucose uptake by using reverse transcriptase-polymerase chain reaction.

Results

All except two colorectal cancer lesions showed increased uptake of FDG. The mean SUV of FDG-PET was 12.0 ± 1.2 (±SEM). The mean mRNA expression levels of GLUT1 and HK2 were significantly higher in cancer tissues than in the surrounding normal mucosa. Moreover, to promote the upregulation of glucose uptake, the expressions of HIF1α and PCNA were induced to 2.6 and 3.3 times higher than that in the normal mucosa. However, the quantitative correlation analysis showed SUV was correlated with HIF1α expression but not with PCNA expression.

Conclusion

Our molecular-based analysis suggested that FDG accumulation due to induction of glucose uptake proteins might be associated with the hypoxic environment in tumors rather than the tumor growth. Therefore, for assessing the efficacy of chemotherapy using FDG-PET, we must keep in mind that SUV does not indicate the tumor growth directly.
Literature
1.
go back to reference Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 1997; 38: 1215–21.PubMed Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 1997; 38: 1215–21.PubMed
2.
go back to reference Aung W, Hasegawa S, Koshikawa-Yano M, et al. Noninvasive assessment of regulable transferred-p53 gene expression and evaluation of therapeutic response with FDG-PET in tumor model. Gene Ther 2010; 17: 1142–51.PubMedCrossRef Aung W, Hasegawa S, Koshikawa-Yano M, et al. Noninvasive assessment of regulable transferred-p53 gene expression and evaluation of therapeutic response with FDG-PET in tumor model. Gene Ther 2010; 17: 1142–51.PubMedCrossRef
3.
go back to reference Janssen MH, Ollers MC, van Stiphout RG, et al. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiother Oncol 2010; 94: 151–5.PubMedCrossRef Janssen MH, Ollers MC, van Stiphout RG, et al. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiother Oncol 2010; 94: 151–5.PubMedCrossRef
4.
go back to reference Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 2005; 26: 315–21.PubMedCrossRef Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 2005; 26: 315–21.PubMedCrossRef
5.
go back to reference Brandi G, Nannini M, Pantaleo MA, et al. Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy 2008; 54: 421–4.PubMedCrossRef Brandi G, Nannini M, Pantaleo MA, et al. Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy 2008; 54: 421–4.PubMedCrossRef
6.
go back to reference Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508–12PubMed Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508–12PubMed
7.
go back to reference Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004; 45: 930–32PubMed Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004; 45: 930–32PubMed
8.
go back to reference Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029–33PubMedCrossRef Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029–33PubMedCrossRef
9.
go back to reference Baserga R. Growth regulation of the PCNA gene. J Cell Sci 1991; 98: 433–6.PubMed Baserga R. Growth regulation of the PCNA gene. J Cell Sci 1991; 98: 433–6.PubMed
10.
go back to reference Hong SS, Lee H, Kim KW. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004; 36: 343–53.PubMedCrossRef Hong SS, Lee H, Kim KW. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004; 36: 343–53.PubMedCrossRef
11.
go back to reference Paudyal B, Oriuchi N, Paudyal P, et al. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008; 22: 83–6.PubMedCrossRef Paudyal B, Oriuchi N, Paudyal P, et al. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008; 22: 83–6.PubMedCrossRef
12.
go back to reference Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792–7.PubMedCrossRef Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792–7.PubMedCrossRef
13.
go back to reference Miyakubo M, Oriuchi N, Tsushima Y, et al. Diagnosis of maxillofacial tumor with l-3-[18F]-fl uoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007; 21: 129–35.PubMedCrossRef Miyakubo M, Oriuchi N, Tsushima Y, et al. Diagnosis of maxillofacial tumor with l-3-[18F]-fl uoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007; 21: 129–35.PubMedCrossRef
14.
go back to reference Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003; 278: 15333–40.PubMedCrossRef Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003; 278: 15333–40.PubMedCrossRef
15.
go back to reference Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996; 56: 1164–7.PubMed Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996; 56: 1164–7.PubMed
16.
go back to reference Gu J, Yamamoto H, Fukunaga H, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-d-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006; 51: 2198–205.PubMedCrossRef Gu J, Yamamoto H, Fukunaga H, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-d-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006; 51: 2198–205.PubMedCrossRef
17.
go back to reference Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 2005; 46: 1753–9.PubMed Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 2005; 46: 1753–9.PubMed
18.
go back to reference Yu Kuang, Schomisch SJ, Chandramouli V, Lee Z. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol 2006; 143: 225–31.CrossRef Yu Kuang, Schomisch SJ, Chandramouli V, Lee Z. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol 2006; 143: 225–31.CrossRef
19.
go back to reference de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008; 19: 348–52.PubMedCrossRef de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008; 19: 348–52.PubMedCrossRef
20.
go back to reference Dimitrakopoulou-Strauss A, Strauss LG, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004; 45: 1480–7.PubMed Dimitrakopoulou-Strauss A, Strauss LG, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004; 45: 1480–7.PubMed
21.
go back to reference Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700–8.PubMed Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700–8.PubMed
22.
go back to reference Byström P, Berglund A, Garske U, et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009; 20: 1057–61.PubMedCrossRef Byström P, Berglund A, Garske U, et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009; 20: 1057–61.PubMedCrossRef
23.
go back to reference Izuishi K, Yamamoto Y, Sano T, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010; 14: 1151–8.PubMedCrossRef Izuishi K, Yamamoto Y, Sano T, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010; 14: 1151–8.PubMedCrossRef
24.
go back to reference Ikenaga N, Otomo N, Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007; 73: 1151–7PubMed Ikenaga N, Otomo N, Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007; 73: 1151–7PubMed
25.
go back to reference Heudel P, Cimarelli S, Montella A, et al. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 2010;15:588–93.PubMedCrossRef Heudel P, Cimarelli S, Montella A, et al. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 2010;15:588–93.PubMedCrossRef
26.
go back to reference Westerterp M, Sloof GW, Hoekstra OS, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008; 134: 227–36.PubMedCrossRef Westerterp M, Sloof GW, Hoekstra OS, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008; 134: 227–36.PubMedCrossRef
27.
go back to reference Warburg O (1930). The metabolism of tumours. London, England: Constable. Warburg O (1930). The metabolism of tumours. London, England: Constable.
28.
go back to reference Robey IF, Stephen RM, Brown KS, et al. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008; 10: 745–56.PubMed Robey IF, Stephen RM, Brown KS, et al. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008; 10: 745–56.PubMed
29.
go back to reference Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927–30.PubMedCrossRef Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927–30.PubMedCrossRef
30.
31.
go back to reference Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891–9.PubMedCrossRef Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891–9.PubMedCrossRef
32.
go back to reference Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg’s effect. J Bioenerg Biomembr 2007; 39: 223–9.PubMedCrossRef Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg’s effect. J Bioenerg Biomembr 2007; 39: 223–9.PubMedCrossRef
33.
go back to reference Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–54.PubMedCrossRef Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–54.PubMedCrossRef
34.
go back to reference Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004; 45: 22–9PubMed Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004; 45: 22–9PubMed
35.
go back to reference Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003; 23: 3263–72PubMed Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003; 23: 3263–72PubMed
36.
go back to reference Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811–7.PubMed Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811–7.PubMed
Metadata
Title
Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography
Authors
Kunihiko Izuishi
Yuka Yamamoto
Takanori Sano
Ryusuke Takebayashi
Yoshihiro Nishiyama
Hirohito Mori
Tsutomu Masaki
Asahiro Morishita
Yasuyuki Suzuki
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 2/2012
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1727-z

Other articles of this Issue 2/2012

Journal of Gastrointestinal Surgery 2/2012 Go to the issue